Paper3918441
Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy.
Leichman L and 9 others. Am J Med, 1985. Cited by 169 papers, by iCite.
Cite this record
ConductScience Library. Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. Papers, record 3918441. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3918441
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anus Neoplasms | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| Carcinoma, Transitional Cell | Major topic |
| Adult | |
| Aged | |
| Antineoplastic Combined Chemotherapy Protocols | |
| Combined Modality Therapy | |
| Female | |
| Fluorouracil | |
| Humans | |
| Male | |
| Middle Aged | |
| Mitomycin | |
| Mitomycins | |
| Preoperative Care |
Source PubMed
Cited by55
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 169 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42583074 | The historical perspective on anal cancer therapy: what have we learnt, where did we fail? | ESMO Gastrointest Oncol | 2026 | https://conductscience.org/library/papers/42583074 | PubMed |
| 42582979 | Optimising chemoradiotherapy in anal cancer. | ESMO Gastrointest Oncol | 2026 | https://conductscience.org/library/papers/42582979 | PubMed |
| 42238726 | More Than Just an Abscess: An Unusual Case of Anal Squamous Cell Carcinoma. | ACG Case Rep J | 2026 | https://conductscience.org/library/papers/42238726 | PubMed |
| 41653360 | SEOM-GEMCAD-TTD clinical guidelines for anal cancer (2025). | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/41653360 | PubMed |
| 41440221 | Outcomes of Anal Cancer Patients with Inflammatory Bowel Disease Treated with Curative Chemoradiotherapy: A Systematic Review of Current Evidence. | Curr Oncol | 2025 | https://conductscience.org/library/papers/41440221 | PubMed |
| 40936687 | Isolated hypoxic pelvic perfusion combined with electroporation is a valid alternative to traditional therapies for anal squamous cell carcinoma: a case study. | Front Oncol | 2025 | https://conductscience.org/library/papers/40936687 | PubMed |
| 40606940 | Anal cancer impact among people with HIV infection - a matched cohort study. | Ecancermedicalscience | 2025 | https://conductscience.org/library/papers/40606940 | PubMed |
| 39312693 | Anal carcinoma - exploring the epidemiology, risk factors, pathophysiology, diagnosis, and treatment. | World J Exp Med | 2024 | https://conductscience.org/library/papers/39312693 | PubMed |
| 39163501 | Treatment of stage I-III squamous cell anal cancer: a comparative effectiveness systematic review. | J Natl Cancer Inst | 2025 | https://conductscience.org/library/papers/39163501 | PubMed |
| 38735904 | Updates on the Version 9 American Joint Committee on Cancer Staging System for Anal Cancer. | Ann Surg Oncol | 2024 | https://conductscience.org/library/papers/38735904 | PubMed |
| 38688457 | Rational treatment options for T1/2N0M0 squamous cell carcinoma of the anal canal: a population-based study combined with external validation. | Oncologist | 2024 | https://conductscience.org/library/papers/38688457 | PubMed |
| 38425766 | Outcomes of patients with anal cancer treated with definitive chemoradiation: A single centre experience. | Ecancermedicalscience | 2024 | https://conductscience.org/library/papers/38425766 | PubMed |
| 36975459 | Anal Cancer: The Past, Present and Future. | Curr Oncol | 2023 | https://conductscience.org/library/papers/36975459 | PubMed |
| 36241859 | Impact of marital status at diagnosis on the survival of patients with anal canal squamous cell carcinoma: a propensity score-matched analysis. | Int J Colorectal Dis | 2022 | https://conductscience.org/library/papers/36241859 | PubMed |
| 34850581 | Construction and validation of a prognostic nomogram for anal squamous cell carcinoma. | Cancer Med | 2022 | https://conductscience.org/library/papers/34850581 | PubMed |
| 34790484 | Definitive Radiotherapy for Patients With Anal Squamous Cell Carcinoma: A Retrospective Cohort Study. | Cureus | 2021 | https://conductscience.org/library/papers/34790484 | PubMed |
| 34663790 | Molecular and genomic characterisation of a panel of human anal cancer cell lines. | Cell Death Dis | 2021 | https://conductscience.org/library/papers/34663790 | PubMed |
| 33925282 | De-Escalation of Therapy for Patients with Early-Stage Squamous Cell Carcinoma of the Anus. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33925282 | PubMed |
| 33801992 | Evolution of the Role of Radiotherapy for Anal Cancer. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33801992 | PubMed |
| 33486535 | Radiotherapy alone versus chemoradiotherapy for stage I anal squamous cell carcinoma: a systematic review and meta-analysis. | Int J Colorectal Dis | 2021 | https://conductscience.org/library/papers/33486535 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3918441
GET https://conductscience.org/api/papers/v1/3918441/cited_by?page=2